Oridonin ameliorates lupus-like symptoms of MRLlpr/lpr mice by inhibition of B-cell activating factor (BAFF)

European Journal of Pharmacology

Volumn 715, Issue 1-3, 2013, Pages 230-237

  Zhou, Lin ^a   Sun, Lijuan ^b,c   Wu, Hongkun ^a   Zhang, Lingzhen ^a   Chen, Mingcang ^b   Liu, Jianwen ^b   Zhong, Renqian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c HUBEI UNIVERSITY   (China)

Author keywords

B cell; BAFF; Isodon Serra; Oridonin; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; CYCLOPHOSPHAMIDE; ORIDONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG DOSE COMPARISON; IN VITRO STUDY; IN VIVO STUDY; ISODON; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEINURIA; SURVIVAL RATE; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION REGULATION;

B CELL; BAFF; ISODON SERRA; MRL(LPR/LPR) MICE; ORIDONIN; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL COUNT; CELL LINE; CREATININE; DITERPENES, KAURANE; DNA; DOWN-REGULATION; FEMALE; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES; MICE; MICE, INBRED MRL LPR; PROMOTER REGIONS, GENETIC; PROTEINURIA; SURVIVAL ANALYSIS;

EID: 84885476331     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.05.016     Document Type: Article

References (23)

1. Becker-Merok, A., Nikolaisen, C., Nossent, H.C., 2006. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 15, 570-576. (Pubitemid 44661743)
2. Dörner, T., Giesecke, C., Lipsky, P.E., 2011. Mechanisms of B cell autoimmunity in SLE. Arthritis Res. Ther. 13, 243-254.
3. Huang, G., Yang, Y.C., Xu, Z.Z., Zhou, P., Gong, W., Yuan, L., Fan, J.S., He, F.T., 2011. Down-regulation of B lymphocyte stimulator expression by curcumin in B lymphocyte via suppressing nuclear translocation of NF-κB. Eur. J. Pharmacol. 650, 451-457.
4. Ju, Z.L., Shi, G.Y., Zuo, J.X., Zhang, J.W., Jian, S., 2007. Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology 120, 281-289. (Pubitemid 46046326)
5. Li, C.Y., Wang, E.Q., Cheng, Y., Bao, J.K., 2011. Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int. J. Biochem. Cell Biol. 43, 701-704.
6. Lied, G.A., Berstad, A., 2011. Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand. J. Immunl 73, 1-7.
7. Liu, J., Yang, F., Zhang, Y., Li, J., 2007. Studies on the cell-immunosuppressive mechanism of Oridonin from Isodon serra. Int. Immunopharmacol. 7, 945-954. (Pubitemid 46702844)
8. Liu, Z., Davidson, A., 2011. BAFF and selection of auto-reactive B cells. Trends Immunl 32, 388-394.
9. Mackay, F., Browning, J.L., 2002. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol. 2, 465-475. (Pubitemid 37328738)
10. Mackay, F., Figget, W.A., Saulep, D., Lepage, M., Hibbs, M.L., 2010. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol. Rev. 237, 205-225.
11. Mackay, F., Schneider, P., 2009. Cracking the BAFF code. Nat. Rev. Immunol. 9, 491-502.
12. Reyes, L.I., Leon, F., Gonzalez, P., Rozas, M.F., Labarca, C., Segovia, A., Neira, O., Naves, R., 2008. Dexaethasone inhibits BAFF expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cytokine 42, 170-178.
13. Stohl, W., Hilbert, D.M., 2012. The discovery and development of belimumab: the anti-BlyS-lupus connection. Nat. Biotechnol. 30, 69-77.
14. Stohl, W., Schol, J.L., Cancro, M.P., 2011. Targeting BlyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr. Opin. Rheumatol. 23, 305-310.
15. Stohl, W., Xu, D., Kim, K.S., Koss, M.N., Jorgensen, T.N., Deocharan, B., Metzger, T.E., Bixler, S.A., Hong, Y.S., Ambrose, C.M., Mackay, F., Morel, L., Putterman, C., Kotzin, B.K., Kalled, S.L., 2005. BAFF over-expression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 52, 2080-2091. (Pubitemid 40994331)
16. Strasser, A., Jost, P.J., Nagata, S., 2009. The many roles of FAS receptor signaling in the immune system. Immunity 30, 180-192.
17. Sun, L., Zhou, L., Chen, M., Zhong, R., Liu, J., 2011. Amelioration of systemic lupus erythematosus by Withangulation A in MRL/lpr mice. J. Cell. Biochem. 112, 2376-2382.
18. Sun, J., Lin, Z., Feng, J., Li, Y., Shen, B., 2008. BAFF-targeting therapy, a promising strategy for targeting autoimmune diseases. Eur. J. Pharmacol. 597, 1-5.
19. Takahashi, T., Tanaka, M., Brannan, C.I., Jenkins, N.A., Copeland, N.G., Suda, T., Nagata, S., 1994. Generalized lympho-proliferative disease in mice, caused by a point mutation in Fas ligand. Cell 76, 969-976. (Pubitemid 24106378)
20. Youinou, P., Pers, J.O., 2010. The late news on baff in autoimmune diseases. Autoimmune Rev. 9, 804-806.
21. Zhang, P., Liu, Y., Feng, N., Xu, J., 2008. Preparation and evaluation of self-micromulsifying drug delivery system of Oridonin. Int. J. Pharm. 355, 269-276.
22. Zhang, Y., Liu, J., Jia, W., Zhao, A., Li, T., 2005. Distinct immunosuppressive effect by Isodon serra extracts. Int. Immunopharmacol. 5, 1957-1965. (Pubitemid 41586234)
23. Zhou, L., Zhong, R., Hao, W., Wang, H., Fan, X., Mi, Q., 2009. Interleukin-10 and interferon-gamma up-regulate the expression of B-cell activating factor in cultured human promyelocytic leukemia cells. Exp. Mol. Pathol. 87, 54-58.